Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 222

Sort by

Sort Order Select

Journal Articles

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Olli Dufva, Jan Koski, Pilvi Maliniemi, Aleksandr Ianevski, Jay Klievink, Judith Leitner, Petri Pölönen, Helena Hohtari, Khalid Saeed, Tiina Hannunen, Pekka Ellonen, Peter Steinberger, Matti Kankainen, Tero Aittokallio, Mikko A. I. Keränen, Matti Korhonen, Satu Mustjoki

Blood (2020) 135 (9): 597–609.

https://doi.org/10.1182/blood.2019002121

Published: 2020

Includes: Supplemental data

Journal Articles

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Lisa C. Holthof, MSc, Hilma J. Van Der Horst, MSc, Renée Poels, Jort T. van der Schans, MSc, Anne T. Gelderloos, MSc, Fengzhi Li, Henk Lokhorst, MD PhD, Sonja Zweegman, MD PhD, Maria Themeli, MD PhD, Niels W. C. J. Van De Donk, Richard W.J. Groen, PhD, Tuna Mutis, MD PhD

Blood (2019) 134 (Supplement_1): 137.

https://doi.org/10.1182/blood-2019-125818

Published: 2019

Journal Articles

A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma

Jason R. Westin, MD, Nathan H. Fowler, MD, Loretta J. Nastoupil, MD MSc, Sattva S Neelapu, MD, Hun Ju Lee, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Raphael E Steiner, MD, Sairah Ahmed, MD, Simrit Parmar, MBBS, Ranjit Nair, MBBS,MD, Rebecca Harrison, MD, Luis Fayad, MD

Blood (2019) 134 (Supplement_1): 4086.

https://doi.org/10.1182/blood-2019-131463

Published: 2019

Journal Articles

First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)

Maja J.A. de Jonge, MD, Benedito A. Carneiro, MD, Lot Devriese, MD PhD, Toshihiko Doi, MD PhD, Sudhir Penugonda, MD MPH, Adam M. Petrich, MD, Silpa Nuthalapati, PhD, Monica Motwani, PhD, Dimple A. Modi, PhD, Yu-Wei Chang, PhD, Emiliano Calvo, MD PhD, Victor Moreno, MD PhD

Blood (2019) 134 (Supplement_1): 3924.

https://doi.org/10.1182/blood-2019-129783

Published: 2019

Journal Articles

A Novel Combination of Drugs Which Target Both the Intrinsic and Extrinsic Apoptotic Pathways to Eliminate Myelofibrosis CD34+ Cells

Min Lu, PhD, Lijuan Xia, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4201.

https://doi.org/10.1182/blood-2019-129017

Published: 2019

Journal Articles

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Namrata S Chandhok, MD, Wei Wei, MD, Stephanie Halene, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 1374.

https://doi.org/10.1182/blood-2019-130033

Published: 2019

Journal Articles

CD34+ Derived Microparticles Regulate Apoptosis in Normal and Acute Myeloid Leukemia Cells

Angeliki Xagorari, PhD, Sarantis Tsetsakos, Bsc, Zoi Katana, Konstantinos Krikonis, undergraduate student, Anastasia Kouvatsi, Katerina Chlichlia, Assistant Professor, Achilles Anagnostopoulos, Damianos Sotiropoulos, MD

Blood (2018) 132 (Supplement 1): 5090.

https://doi.org/10.1182/blood-2018-99-114425

Published: 2018

Journal Articles

CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis

Nathan Singh, MD, Olga Shestova, PhD, Katharina Hayer, Albert Hong, Pranali Ravikumar, MS, Atushi Hoshino, MD PhD, Ophir Shalem, PhD, Matthew D. Weitzman, PhD, Carl H June, MD, Saar I. Gill, MDPhD, Marco Ruella, MD

Blood (2018) 132 (Supplement 1): 698.

https://doi.org/10.1182/blood-2018-99-117328

Published: 2018

Journal Articles

Ubiquitin-Activating Enzyme E1 Inhibition Caused Acute Leukemia Cell Apoptosis By Affecting CHOP Pathway

Ju Bai, PhD, Aili He, MD, Jianli Wang, MD, Yun Yang, MD, Ying Shen, MD, Yuandong Feng, MD, Yan Xu

Blood (2018) 132 (Supplement 1): 2784.

https://doi.org/10.1182/blood-2018-99-118162

Published: 2018

Journal Articles

Identification of Molecular Markers of Tumor Cell Sensitivity and Resistance to Natural Killer Cells through Genome-Wide CRISPR Activation and CRISPR Editing Screens in Multiple Myeloma Cell Lines: Implications for Anti-Myeloma Immunotherapy

Sara Gandolfi, MD, Michal Sheffer, PhD, Emily Lowry, Olga Dashevsky, PhD, Ryosuke Shirasaki, MD PhD, Ricardo De Matos Simoes, PhD, Constantine S. Mitsiades, MD PhD

Blood (2018) 132 (Supplement 1): 1115.

https://doi.org/10.1182/blood-2018-99-118736

Published: 2018

Journal Articles

High-Level Setd8 Expression Is Important for Establishment of Normal Patterns of Erythroid Gene Expression and Is Essential for Stress Erythropoiesis

Tyler A Couch, BS, Zachary C. Murphy, PhD, Jacquelyn Lillis, MS, Michael Getman, MS, Paul D. Kingsley, PhD, Ryo Kurita, PhD, Yukio Nakamura, MD PhD, Laurie A. Steiner, MD

Blood (2018) 132 (Supplement 1): 499.

https://doi.org/10.1182/blood-2018-99-116609

Published: 2018

Journal Articles

A Novel PU.1 - Caspase 8/cFLIP Axis in Neutrophil and Macrophage Differentiation of AML Cells

Magali Humbert, PhD, Mario P. Tschan, PhD, Aladin Haimovici, Bruce E. Torbett, PhD, Nicolas Niklaus, MSc, BSc

Blood (2018) 132 (Supplement 1): 1347.

https://doi.org/10.1182/blood-2018-99-112797

Published: 2018

Journal Articles

Identification and Validation of Molecular Markers of Tumor Cell Resistance to Natural Killer Cells through CRISPR-Based Screens and Large-Scale Phenotypic Screens of Pooled Tumor Cell Lines

Michal Sheffer, PhD, Lotte Wieten, PhD, Channing Yu, MD PhD, Yiguo Yu, PhD, Olga Dashevsky, PhD, Emily Lowry, Jennifer Roth, Aviad Tsherniak, PhD, Chris C Mader, Sam Bender, Jordan Bryan, Cong Zhu, Li Wang, Ricardo De Matos Simoes, PhD, Sara Gandolfi, MD, Eugen Dhimolea, PhD, Megan Bariteau, Todd R. Golub, MD, Constantine S. Mitsiades, MD PhD

Blood (2017) 130 (Supplement 1): 623.

https://doi.org/10.1182/blood.V130.Suppl_1.623.623

Published: 2017

Journal Articles

RNA Sequencing Reveals Mechanisms Underlying Modulation of Hodgkin Lymphoma Cells and Tumor Microenvironment By the PI3K δ/γ Inhibitor, RP6530

Silvia Laura Locatelli, PhD, Francesca Maria Consonni, PhD, Giuseppa Careddu, Simone Serio, Srikant Viswanadha, PhD, Swaroop Kumar VS Vakkalanka, PhD, Lucia Morello, MD, Massimo Magagnoli, MD, Luca Castagna, MD, Armando Santoro, MD, Antonio Sica, PhD, Carmelo Carlo-Stella, MD

Blood (2017) 130 (Supplement 1): 2476.

https://doi.org/10.1182/blood.V130.Suppl_1.2476.2476

Published: 2017

Journal Articles

Bone Marrow Infiltrating T-Cell Signatures Following Allo-HCT for Adult Acute Lymphoblastic Leukaemia Differentiate between Patients in Continuous CR and Those with Persistent Minimal Residual Disease or Relapse

Dina Ahmed Said Aly Okasha, MBBS, MSc, Amy A Kirkwood, Krisztina Zuborne Alapi, MSc, Rachel J Mitchell, MSc, Pedro Santos e Sousa, MD PhD, Daniel Leongamornlert, PhD, Elli Papaemmanuil, PhD, David Marks, MD PhD, Ronjon Chakraverty, BMBS, PhD, Adele K Fielding, MBBS,PhDFRCP,FRCPath

Blood (2017) 130 (Supplement 1): 1317.

https://doi.org/10.1182/blood.V130.Suppl_1.1317.1317

Published: 2017

Journal Articles

TET2 Deficiency Led to Expansion of Dysfunctional Erythroid Progenitors

Xiaoli Qu, MS, Lixiang Chen, Yaomei Wang, Yumin Huang, John Hale, Wei Li, Huizhi Zhao, Shijie Zhang, Xinhua Guo, Abdullah Mahmood Ali, PhD, Azra Raza, MD, Mohandas Narla, DSc, Qiaozhen Kang, PhD, Xiuli An, MD PhD

Blood (2017) 130 (Supplement 1): 2202.

https://doi.org/10.1182/blood.V130.Suppl_1.2202.2202

Published: 2017

Journal Articles

ONC213, a Novel Second Generation Analog of ONC201, Shows Promising Anti-Leukemic Activity Against AML Cells In Vitro and In Vivo

Yongwei Su, Xinyu Li, Holly Edwards, Joshua E. Allen, PhD, Martin Stogniew, Varun Vijay Prabhu, BPharm, MS, PhD, Jeffrey W. Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2017) 130 (Supplement 1): 3822.

https://doi.org/10.1182/blood.V130.Suppl_1.3822.3822

Published: 2017

Journal Articles

Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization

Blood (2017) 130 (Supplement 1): 2720.

https://doi.org/10.1182/blood.V130.Suppl_1.2720.2720

Published: 2017

Journal Articles

Abbv-621 Is a Novel and Potent TRAIL Receptor Agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors

Stephen Kenneth Tahir, PhD, Morey L Smith, MS, Larry R Solomon, PhD, Haichao Zhang, PhD, John C Xue, MD, Yu Xiao, MS, Dong Cheng, MS, Greg Buchanan, PhD, Susan Morgan-Lappe, PhD, Darren C. Phillips, PhD

Blood (2017) 130 (Supplement 1): 2812.

https://doi.org/10.1182/blood.V130.Suppl_1.2812.2812

Published: 2017

Journal Articles

Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding

Hilma J van der Horst, Marije B Overdijk, Esther CW Breij, Martine Chamuleau, MD PhD, Henk M Lokhorst, Tuna Mutis, PhD

Blood (2017) 130 (Supplement 1): 1835.

https://doi.org/10.1182/blood.V130.Suppl_1.1835.1835

Published: 2017

NARROW

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma

First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)

A Novel Combination of Drugs Which Target Both the Intrinsic and Extrinsic Apoptotic Pathways to Eliminate Myelofibrosis CD34+ Cells

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

CD34+ Derived Microparticles Regulate Apoptosis in Normal and Acute Myeloid Leukemia Cells

CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis

Ubiquitin-Activating Enzyme E1 Inhibition Caused Acute Leukemia Cell Apoptosis By Affecting CHOP Pathway

Identification of Molecular Markers of Tumor Cell Sensitivity and Resistance to Natural Killer Cells through Genome-Wide CRISPR Activation and CRISPR Editing Screens in Multiple Myeloma Cell Lines: Implications for Anti-Myeloma Immunotherapy

High-Level Setd8 Expression Is Important for Establishment of Normal Patterns of Erythroid Gene Expression and Is Essential for Stress Erythropoiesis

A Novel PU.1 - Caspase 8/cFLIP Axis in Neutrophil and Macrophage Differentiation of AML Cells

Identification and Validation of Molecular Markers of Tumor Cell Resistance to Natural Killer Cells through CRISPR-Based Screens and Large-Scale Phenotypic Screens of Pooled Tumor Cell Lines

RNA Sequencing Reveals Mechanisms Underlying Modulation of Hodgkin Lymphoma Cells and Tumor Microenvironment By the PI3K δ/γ Inhibitor, RP6530

Bone Marrow Infiltrating T-Cell Signatures Following Allo-HCT for Adult Acute Lymphoblastic Leukaemia Differentiate between Patients in Continuous CR and Those with Persistent Minimal Residual Disease or Relapse

TET2 Deficiency Led to Expansion of Dysfunctional Erythroid Progenitors

ONC213, a Novel Second Generation Analog of ONC201, Shows Promising Anti-Leukemic Activity Against AML Cells In Vitro and In Vivo

Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization

Abbv-621 Is a Novel and Potent TRAIL Receptor Agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors

Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only